Syphilis screening coverage and positivity by HIV treatment status among South African pregnant women enrolled in the 2019 antenatal HIV sentinel survey.
Female
Pregnancy
Humans
Adolescent
Young Adult
Adult
Middle Aged
Syphilis
/ diagnosis
HIV Infections
/ complications
Pregnant Women
Pregnancy Complications, Infectious
/ diagnosis
Cross-Sectional Studies
South Africa
/ epidemiology
Infectious Disease Transmission, Vertical
Penicillin G Benzathine
/ therapeutic use
Anti-Retroviral Agents
/ therapeutic use
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
21
12
2022
accepted:
28
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
We describe coverage of maternal syphilis screening, syphilis positivity, coverage of treatment and their association with maternal HIV infection and antiretroviral treatment (ART) status among pregnant women attending South African antenatal clinics. The 2019 antenatal care sentinel survey was a cross-sectional survey conducted from 1 October to 15 November 2019 at 1589 sentinel sites in all nine provinces of the country and aimed to enrol 36,000 pregnant women ages 15-49 years regardless of HIV, ART or syphilis status. Data collection procedures included obtaining written informed consent, a brief interview, medical record review and blood specimen collection. Completed data collection forms and specimens were sent to designated regional laboratories for data capture and HIV serology testing. Data analysis determined four outcomes i) syphilis screening coverage ii) syphilis positivity iii) coverage of any treatment and iv) with Benzathine penicillin G (BPG). Multivariable logistic regression models with or without interaction between HIV infection and ART status with province were used to determine factors associated with syphilis positivity. Of the 41 598 women enrolled, 35 900 were included in the analysis for syphilis screening coverage. The weighted syphilis screening coverage was 96.4% [95% Confidence Interval (CI) 95.9-96.7%] nationally and was lowest among HIV positive women not on ART at 93.5% (95% CI 92.2-94.5%). Syphilis positivity was 2.6% (95% CI 2.4-2.9%) nationally. Among those who were syphilis positive, 91.9% (95% CI 89.8-93.7%) had documentation of syphilis treatment status, of whom 92.0% (95% CI 89.8-93.9%) were treated, with the majority treated with one or more doses of BPG [92.2% (95% CI 89.8-94.3%)]. HIV-positive women, not on ART [adjusted odd ratio (aOR) 2.24 (95% 1.71-2.93)] and those on ART [aOR 2.25 (95% CI 1.91-2.64)] were more likely to be syphilis positive compared to those who were HIV negative. The national syphilis screening coverage met the global screening target of 95%. Syphilis positivity was higher among HIV positive women compared to negative women. Introduction of rapid syphilis testing and ensuring a universal supply of appropriate treatment for syphilis will reduce the likelihood of mother-to-child transmission of syphilis.
Identifiants
pubmed: 37005466
doi: 10.1038/s41598-023-32456-0
pii: 10.1038/s41598-023-32456-0
pmc: PMC10067819
doi:
Substances chimiques
Penicillin G Benzathine
RIT82F58GK
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
5322Subventions
Organisme : PEPFAR
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Int J Equity Health. 2021 Mar 15;20(1):77
pubmed: 33722225
PLoS One. 2019 Feb 27;14(2):e0211720
pubmed: 30811406
Int J STD AIDS. 2017 Jan;28(1):45-53
pubmed: 26692548
Bull World Health Organ. 2013 Mar 1;91(3):217-26
pubmed: 23476094
Reprod Health. 2019 Mar 4;16(1):27
pubmed: 30832694
Sex Transm Dis. 2017 Jun;44(6):371-375
pubmed: 28499289
Lancet Glob Health. 2021 Jan;9(1):e61-e71
pubmed: 33227254
Sex Transm Infect. 2021 Nov;97(7):525-533
pubmed: 33219164
J Matern Fetal Neonatal Med. 2022 Dec;35(25):5828-5833
pubmed: 33678095
PLoS Med. 2017 Dec 27;14(12):e1002473
pubmed: 29281619
Pan Afr Med J. 2017 Sep 07;28:8
pubmed: 29138654
BMC Infect Dis. 2018 Mar 6;18(1):109
pubmed: 29510664
Curr HIV/AIDS Rep. 2021 Aug;18(4):280-288
pubmed: 34091858
BMC Pregnancy Childbirth. 2020 Oct 27;20(1):648
pubmed: 33109116
PLoS One. 2020 Nov 13;15(11):e0241999
pubmed: 33186360
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):e135-e140
pubmed: 31295173
Sex Transm Infect. 2017 Aug;93(5):374-378
pubmed: 28093460
Pediatr Infect Dis J. 2015 Mar;34(3):e52-7
pubmed: 25742089
Medicine (Baltimore). 2017 Jan;96(2):e5849
pubmed: 28079818
AIDS Care. 2020 May;32(5):651-655
pubmed: 31690082
BMJ Open. 2020 Oct 5;10(10):e043763
pubmed: 33020109